Insider Buy Confluence Report — Past 7 Days (Apr 28 – May 4, 2026)
ARES — Ares Management (May 4)
Insider Signal: Strong (3) — Director Ashish Bhutani purchased $1.3M at $127/share, materially above the prevailing market price of $119. Zero insider selling over the past year. 1.7% insider ownership ($684M). Buy Discount: Insider paid a ~7% premium to market — not a discount buy, but voluntarily overpaying is an exceptionally rare and high-conviction signal. Monthly: Neutral/Bullish — Record AUM ($644B, +18% YoY), $9.8B ASOF III fundraise. Shadows: 5% withdrawal cap imposed on $10.7B fund (liquidity stress), CDX index inclusion enabling short sellers, Q4 earnings miss triggered 14.4% plunge. Weekly: Bullish — Q1 fee-related earnings +26% to $464M, 46% YoY capital raise growth, 20% dividend increase. Aspida IPO catalyst in 18–24 months. Headwind: M&A activity down 41%. Daily: Bullish — $30B gross capital raised (+46% YoY), $100B+ credit dry powder, healthcare infrastructure bet (GMR Solutions), ARCC $800M debt offering shows capital market access. Operational strength undeniable. Vol Context: High (alt-asset manager, sector liquidity stress) — High risk tier. Confluence: SOLID Key Insight: Buying a full $1.3M worth at a premium to market is nearly unheard-of — it signals Bhutani believes the current price is a bargain relative to intrinsic value, not just fair. Strong operational data (22% management fee growth, record fundraising) backs the thesis. Primary risk is the BDC redemption pressure and sector-wide short-seller targeting via the CDX index inclusion. Size conservatively given elevated volatility.
ABT — Abbott Laboratories (May 2)
Insider Signal: Strong (3) — Director Daniel J. Starks purchased 10,000 shares at $92.65 ($927K) near the 52-week low; CFO Philip Boudreau also acquired 2,200 shares indirectly. Two insiders, including a board member holding 6.75M shares.
Buy Discount: Stock near 52-week low, down ~29% YTD → estimated 0–5th percentile of 52W range. Maximum-conviction buy-the-floor signal.
Monthly: Neutral — Strong innovation (FreeStyle Libre OTC clearance, Cancerguard multi-cancer test, PFA cardiac platform at 98.3% safety). Severe headwinds: $70M Similac jury verdict + 1,700 pending NEC lawsuits, Exact Sciences acquisition causing $0.20 EPS dilution, downward full-year guidance revision.
Weekly: Bullish — FDA clearance for Ultreon 3.0 AI-powered cardiac OCT device is a genuine clinical moat. Insider buy at the lows is a powerful counter-narrative. Risk: Polen Capital strategic exit.
Daily: Bullish — New glucose monitoring FDA approval, Q2 earnings beat, 9% YoY diabetes care revenue growth. Slight stock dip on cautious guidance (already priced in near the lows).
Vol Context: Mid-High (healthcare mid-cap under litigation) — Mid risk tier.
Confluence: SOLID
Key Insight: Insider buying at the 52-week floor with a $927K single transaction by a board member who already holds 6.75M shares is a classic "management knows something the market doesn't" signal. The innovation pipeline (Cancerguard, PFA, FreeStyle Libre OTC) provides genuine catalysts. The critical risk is the Similac litigation — 1,700+ pending NEC lawsuits could create sustained headline pressure. Best framed as a long-duration recovery trade, not a near-term flip.
SPGI — S&P Global (May 2)
Insider Signal: Strong (3) — CEO Martina Cheung purchased 2,322 shares at $429.93 (~$1M), increasing her stake by 9.22%. CEO-level open-market buy is a rare and high-conviction signal. Buy Discount: Stock down ~19% YTD, trading ~23% below analyst consensus target. Mid-range of 52W (approximately 30–40th percentile). Monthly: Neutral — Dominant data moat (CDX private credit index, iLEVEL private markets analytics, Titan AI platform, Enertel AI acquisition). But Q4 EPS miss despite revenue beat, Zacks Rank #4 (Sell), valuation debate ($538 analyst target vs. $387 DCF fair value). Weekly: Bullish — Q1 2026 beat: 10.4% YoY revenue, 13.7% EPS growth. CEO's $1M personal buy is the week's headline positive. Counter-signal: Tom Gayner (Markel) reduced SPGI stake by 22% — notable exit from a quality-focused investor. Daily: Bullish — Free cash flow moat, "superior long-term compounder" framing vs peers, structural relevance in AI-driven analytics era. Barclays CEO fireside chat on May 5 is a near-term catalyst. Vol Context: Low-Mid (financial data utility) — Low risk tier. Confluence: SOLID Key Insight: CEO spending $1M of personal capital at a beaten-down price is a high-grade signal. The fundamental business (ratings, indices, data) has pricing power and recurring revenues that make it structurally durable. The Gayner exit is the key divergence to monitor — he's a disciplined long-term value investor, so his exit suggests valuation concern. If Q2 2026 shows EPS recovery, this setup becomes HIGH CONVICTION. Current status: strong entry narrative with one prominent contrarian data point.
KO — Coca-Cola (Apr 30)
Insider Signal: Moderate (2) — The entire board of directors purchased phantom shares at $75.81 on April 1, 2026. Note: phantom shares are compensation-linked (board fee policy), not open-market cash purchases — this reduces signal purity vs. a true voluntary buy, but coordinated board-level commitment still carries weight. Buy Discount: Not applicable (compensation mechanism, not market purchase). Monthly: Neutral — Q1 2026 beat ($12.5B revenue, best growth in ~2 years), 13% Zero Sugar volume surge, Marriott partnership win (ending Pepsi's 34-year deal). Risks: BODYARMOR $960M impairment, IRS tax dispute, premium valuation (23x PE). Weekly: Bullish — 8–9% full-year EPS guidance upgrade, 35% operating margin, strong execution. Board phantom share purchase as coordinated confidence signal. Daily: Bullish — 18% adjusted EPS surge, 10% organic sales growth, 12% revenue growth. Buffett's $31B stake intact. Zero Sugar at 13% volume growth confirms consumer pivot thesis is working. Vol Context: Low (consumer staples, Dividend King) — Low risk tier. Confluence: SOLID Key Insight: The "insider" signal here is softer than it appears — phantom shares are a compensation policy, not discretionary open-market buying. However, the underlying business is delivering: Q1 2026 results were genuinely strong, Zero Sugar growth addresses the GLP-1 concern, and the 64-year dividend streak is intact. Primary tail risk is the IRS tax dispute, which remains unquantified. Suitable as a defensive compounder position, not a high-upside trade.
CHTR — Charter Communications (Apr 30 & May 2)
Insider Signal: Strong (3) — CEO Christopher Winfrey purchased 6,936 shares at ~$172/share (+ 3,468 shares via spouse). Directors Wade Davis ($173.72) and Nair Balan ($175.46) also bought on April 28. Coordinated multi-insider buying above the then-prevailing market price of $159. Largest insider buy cluster in 12+ months.
Buy Discount: Insiders bought ABOVE market price at the time ($172 vs. ~$159 market) — paradoxically indicates deep forward conviction, not a discount buy. High conviction but elevated entry.
Monthly: Bearish — 4 consecutive EPS misses, -120K broadband subscribers (worst quarter yet), $94.3B debt, 43% stock decline over past year, shareholder lawsuit, 25.8% advertising revenue collapse.
Weekly: Mixed — The insider buying is the primary positive. JPMorgan downgraded to Neutral ($215 target). 29% stock plunge post-Q1 earnings. Fiber expansion ($7B) is long-dated catalyst.
Daily: Neutral — Leadership promotion (Dave Rodrian to SVP), WiFi 7 and Speed Boost rollout. No subscriber turnaround data yet.
Vol Context: High (leveraged telecom turnaround) — High risk tier.
Confluence: MIXED
Key Insight: The coordinated insider buying — including a CEO purchase above market price — is a powerful signal in isolation. But CHTR is a clear case of "insider conviction vs. deteriorating fundamentals": 4 straight earnings misses, massive debt load, and competitive broadband erosion tell a difficult operational story. This is a contrarian/early-inflection candidate — the key question is whether the $7B fiber build-out can eventually reverse subscriber losses. Not appropriate for low-risk capital. Wait for at least one quarter of stabilizing broadband metrics before treating as HIGH CONVICTION.
NOK — Nokia (Apr 28)
Insider Signal: Moderate (2) — Board member Timo Ihamuotila purchased 50,000 shares at €9.0961 on April 28. However, a separate insider (senior exec Stephan Prosi) sold 15,000 shares at €10.045 the same week — a conflicting signal within the same insider cohort. Buy Discount: Stock up +100% YTD and +92% in 12 months — Ihamuotila's buy is near multi-year highs, not a discount purchase (high percentile of 52W range). Monthly: Mixed — Exceptional AI/cloud pivot (49% YoY AI/cloud sales surge, Nvidia $1B investment, 5G Cloud-RAN monopoly, €629M FCF). But: 75.89x P/E, 20.3% DCF overvaluation, priced for perfection. Weekly: Mixed — Strong institutional and narrative momentum (Oaktree stake, 62% QoQ optical network growth). Insider sell by Stephan Prosi is a notable red flag alongside Ihamuotila's buy. Daily: Bullish — Jim Cramer endorsement, FWA divestiture as strategic clarity signal, board compensation tied to shares (systematic alignment). Vol Context: High (tech turnaround story, up 100% YTD, speculative) — High risk tier. Confluence: MIXED Key Insight: The fundamental transformation at Nokia is real (Nvidia partnership, AI-RAN leadership, 49% cloud sales growth). But the stock has already delivered the entire re-rating — up 100% YTD — making the insider buy at these levels a bet on further multiple expansion, not a value signal. The concurrent insider sale by another senior exec is a meaningful offset. This is a momentum/narrative trade, not an insider-backed value setup. Any stumble in AI-RAN execution or 6G timeline could trigger a sharp reversal.
IP — International Paper (May 2)
Insider Signal: Moderate (2) — Director Scott Tozier purchased 10,000 shares at $31.30 ($313K) on May 1, 2026. Single director, moderate dollar amount.
Monthly: Bearish — $2.8B net loss despite $23.6B revenue, goodwill impairments, restructuring charges. NORPAC acquisition ($360M) is the turnaround bet.
Weekly: Sparse — April 20 weekly had no IP events. April 27 weekly primarily cited the insider buy itself.
Daily: Sparse — April 30 and May 1 daily entries were blank. May 2 daily only discussed the insider purchase.
Vol Context: Mid (industrial turnaround) — Mid risk tier.
Confluence: MIXED
Key Insight: The insider buy is a real signal, but narrative coverage of IP is thin and the underlying financials are deeply challenged ($2.8B net loss). There's insufficient multi-timeframe data to establish confident momentum direction. The investment thesis rests entirely on the NORPAC integration and European containerboard pricing recovery — both high-execution-risk bets. Treat as speculative with limited conviction.
Notable Buyback / Institutional Signals (Past 7 Days — not traditional insiders)
| Ticker | Signal | Details | Strength |
|---|---|---|---|
| ZION | Corporate buyback | $75M share repurchase in Q1 2026 | Moderate |
| ING | Corporate buyback | 1.35M shares at €24.06 (99.5% complete) | Moderate |
| SCHW | Corporate buyback | $4.58B over past 12 months | Moderate |
| WAB | Buyback completion | $1.46B program completed | Moderate |
| HSIC | Institutional | Greenlight Capital (Einhorn) added 460K shares | Moderate |
| UPST | Institutional | Halter Ferguson $37M stake (8.3% of assets) | Moderate |
| FNV | Institutional | Tom Gayner (Markel) added 25K shares to 708K total | Moderate |
| HOOD | Institutional | ARK Invest (Cathie Wood) $39.7M across 3 funds | Low-Moderate |
| NYT | Institutional | Berkshire Hathaway (Buffett) accumulating shares | Moderate |
Ranked Summary Table
| Rank | Ticker | Insider Signal | Narrative Momentum | Vol Tier | Confluence | Key Factor |
|---|---|---|---|---|---|---|
| 1 | ARES | Strong (3) | Bullish | High | SOLID | Director buys ABOVE market; zero insider selling; record operational metrics |
| 2 | ABT | Strong (3) | Bullish | Mid-High | SOLID | Director buy at 52W low (-29% YTD); innovation pipeline intact |
| 3 | SPGI | Strong (3) | Bullish | Low | SOLID | CEO $1M buy; beaten-down quality compounder; Gayner exit is the key risk |
| 4 | KO | Moderate (2) | Bullish | Low | SOLID | Board phantom shares (compensation-linked); strong Q1 execution; defensive |
| 5 | CHTR | Strong (3) | Bearish | High | MIXED | CEO + 2 directors buy above market; fundamentals still deteriorating |
| 6 | NOK | Moderate (2) | Bullish | High | MIXED | +100% YTD; insider buy at highs; conflicting insider sell same week |
| 7 | IP | Moderate (2) | Neutral/Sparse | Mid | MIXED | Thin coverage; $2.8B net loss; single director buy |
Top 3 setups: ARES, ABT, and SPGI have the strongest confluence of insider conviction, narrative backing, and risk-adjusted positioning. ABT is the standout value setup given the 52W-low entry by a sitting director — the key risk to size around is Similac litigation overhang.